October 15, 2020

ICGEB together with AC Immune: recipients of an EU JNDP grant

Grant from the ‘EU Joint Programme – Neurodegenerative Disease Research’ (JPND) provides €1.45M in funding – among the recipients, ICGEB’s Molecular Pathology lab, headed by Emanuele Buratti. The project aims to investigate a TDP-43 aggregation tracer for diagnostic purposes.

Lausanne, Switzerland, October 9, 2020 – AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, has announced that a highly competitive European Union grant has been awarded to support the partnership between AC Immune and the JPND ImageTDP-43 consortium to accelerate development of the Company’s first-in-class TDP-43 positron emission tomography
(PET) tracer.

The grant, which is awarded in response to the European Union JPND’s call for novel imaging and brain stimulation methods and technologies related to neurodegenerative diseases, will be spearheaded through a world-class collaboration with the University of Zurich, Fondazione Santa Lucia-IRCCS, Skåne University Hospital, the International Centre for Genetic Engineering and Biotechnology, and the Erasmus University Medical Center through the JPND’s ImageTDP-43 Consortium.

Press Release:

AC Immune: Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune’s First-in-Class TDP-43 Diagnostic Agent

  • pTDP-43S375 immunoreactivity in ALS–TDP. pTDP-43S375 immunohistochemistry robustly labels the complete spectrum of pathological TDP-43 inclusions present in ALS–TDP. Specifically, diffuse and compact neuronal cytoplasmic inclusions (NCI) in the spinal cord
    sporadic ALS–TDP
  • Emanuele Buratti
  • RNA-protein interactions. Defective RNA processing and neurodegeneration. Genetic disease caused by defective splicing.
    RNA-protein interactions.